Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis

References

• Guiducci S, Giacomelli R, Matucci-Cerinic M. Vascular com-plications of scleroderma. Autoimmun Rev. 2007;6:520–3.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364:603–10.
   Google Scholar
• Caplice NM, Doyle B. Vascular progenitor cells: origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem Cells Dev. 2005;14:122–39.
   PubMed Web of Science ®Google Scholar
• Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol. 2006;18:594–600.
   PubMedGoogle Scholar
• Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467–78.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Increase in circulating endothelial precursors by ator-vastatin in patients with systemic sclerosis. Arthritis Rheum. 2006;54:1946–51.
   PubMed Web of Science ®Google Scholar
• Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phe-nomenon and digital ulcers. J Rheumatol. 2008;35:1801–8.
   PubMed Web of Science ®Google Scholar
• Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D'Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002;46:2410–20.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Lachenbruch PA, Seibold JR, White B, Weiner S, Martin RW, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–5.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear anti-bodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37:75–83.
   Google Scholar
• Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34± cells identifies a population of functional endothelial precursors. Blood. 2000;95:952–8.
   PubMed Web of Science ®Google Scholar
• Distler JH, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, et al. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009;68:163–8.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Cortiana M, Vitali C, Silvestris I, Maglione W, Comina DP, et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol. 2008;35:1323–8.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Yasuda S, Amengual 0, Horita T, Atsumi T, Koike T. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis. 2006;65: 1118–20.
   Google Scholar
• Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholes-terolemic animals. Nat Med. 2000;6:1004–10.
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108: 391–7.
   Google Scholar
• Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399–405.
   PubMed Web of Science ®Google Scholar
• Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelializa-tion: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017–24.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006;54:2605–15.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007;56:1994–2004.
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely cor-relate with risk factors for coronary artery disease. Circ Res. 2001 ;89:E1–7.
   PubMed Web of Science ®Google Scholar
• Zhu S, Evans S, Yan B, Povsic TJ, Tapson V, Goldschmidt-Clermont PJ, et al. Transcriptional regulation of Bim by FOX03a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation. 2008;118: 2156–65.
   Google Scholar